Benzinga | Feb 26, 2021 05:17AM EST

Chardan Capital Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $203

Chardan Capital analyst Michael Morabito maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $202 to $203.